TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Assessing Symptomatic Clinical Episodes in Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Currently meets DSM-5 criteria for MDD~* Body mass index (BMI) between 18 and 40 kg/m\^2, inclusive~* Agree to use adequate method of contraception for the duration of the study~* Additional criteria may apply~Exclusion Criteria:~* Suicide risk~* History of treatment resistance in current depressive episode~* History of electroconvulsive therapy, vagus nerve stimulation, transcranial magnetic stimulation or any experimental central nervous system treatment during the current episode or in the past 6 months~* Pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study~* Additional criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- AXS-05 (Type: EXPERIMENTAL): None
- Bupropion (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Has histologically confirmed non-resectable, metastatic gastric adenocarcinoma including adenocarcinoma of the gastroesophageal junction.~2. Has previously received at least 2 prior regimens for advanced disease and were refractory to or unable to tolerate their last prior therapy.~3. Has measureable or nonmeasurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria.~4. Is able to take medications orally (ie, no feeding tube).~5. Has an Eastern Cooperative Oncology Group performance status of 0 or 1.~6. Has adequate organ function as defined by protocol defined labs.~7. Women of childbearing potential must have a negative pregnancy test and must agree to adequate birth control if conception is possible. Males must agree to adequate birth control.~Exclusion Criteria:~1. Has certain serious illnesses or medical conditions~2. Has had certain other recent treatment e.g. major surgery, anticancer therapy, extended field radiation, received investigational agent within the specified time frames prior to study drug administration.~3. Has previously received TAS-102.~4. Has unresolved toxicity of greater than or equal to Common Terminology Criteria for Adverse Events Grade 2 attributed to any prior therapies.~5. Is a pregnant or lactating female.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TAS-102+BSC (Type: EXPERIMENTAL): Participants received 35 milligrams per meter square (mg/m\^2) of TAS-102 tablets orally twice daily (BID) for 5 days per week (i.e., from Days 1 to 5 and Days 8 to 12) for 2 weeks followed by 14 days rest in each 28-day cycle along with BSC until a discontinuation criterion (participant withdrawal, disease progression, irreversible treatment-related Grade 4 non-hematologic event, physician's decision, pregnancy or death) was met.
- Placebo+BSC (Type: EXPERIMENTAL): Participants received 35 mg/m\^2 of matching placebo for TAS-102 tablets orally BID for 5 days per week (i.e., from Days 1 to 5 and Days 8 to 12) for 2 weeks followed by 14 days rest in each 28-day cycle along with BSC until discontinuation criterion (participant withdrawal, disease progression, irreversible treatment-related Grade 4 non-hematologic event, physician's decision, pregnancy or death) was met.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 18 Years in Taiwan

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy subjects from 2 up to and including 18 years of age~2. Who are in good health as determined by : medical history, physical exam,clinical judgment of the investigator, who have a negative urine pregnancy test for female subjects ≥11 years of age~Exclusion Criteria:~Individuals not eligible to be enrolled in the study were those:~1. Who had a previous confirmed or suspected disease caused by N. meningitidis.~2. Who had household contact with and/or intimate exposure to an individual with culture-proven N. meningitidis infection within 60 days prior to enrolment.~3. Who have previously been immunized with a meningococcal vaccine or vaccine containing meningococcal antigen(s) (licensed or investigational).~4. Who have received any vaccines within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to enrolment in this study or who are planning to receive any vaccine within 30 days from the study vaccines.~5. Who have experienced within the 7 days prior to enrolment significant acute infection or have experienced fever within 3 days prior to enrolment.~6. Who have any serious acute, chronic or progressive who have epilepsy or any progressive neurological disease or history of Guillain-Barre syndrome.~7. Who have a history of any anaphylaxis, serious vaccine reactions, or allergy to any vaccine components.~8. Who have a known or suspected impairment/alteration of immune function, either congenital or acquired~9. Who are known to have a bleeding diathesis, or any condition that may be associated with a prolonged bleeding time.~10. Who have Down's syndrome or other known cytogenic disorders.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- 2-18 years (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Moxifloxacin As Part of a Multi-Drug Regimen For Tuberculosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Presumptive diagnosis of smear-positive pulmonary TB within 2 weeks of study entry. Patients with both pulmonary and extrapulmonary disease are eligible.~* Documentation of HIV infection status. If HIV status is unknown at study entry, the participant must consent to testing and results must be available prior to study participation.~* Agree to use acceptable methods of contraception~Exclusion Criteria:~* History of adverse drug reaction to MOX, INH, RIF, PZA, or EMB~* Disease or condition for which MOX, INH, RIF, PZA, or EMB is contraindicated~* History of more than 14 days of continuous antituberculosis therapy during the previous 2 years or more than 2 months of antituberculosis therapy ever~* Active AIDS-related opportunistic infection or malignancy~* Currently receiving or planning to receive HIV protease inhibitors or nonnucleoside reverse transcriptase inhibitors in the first 2 months after study entry~* Silicotuberculosis~* Central nervous system TB~* Pregnant or breastfeeding~* Unable to take oral medication~* Electrocardiogram (EKG) QTc interval greater than 450 msec~* Taking classes IA or III antiarrhythmic agents (quinidine, procainamide, amiodarone, sotalol), cisapride, erythromycin, perphenazine/amitriptyline, phenothiazines, or tricyclic antidepressant~* Diseases or conditions for which treatment with other drugs with antituberculosis activity (e.g., rifabutin for MAC prophylaxis) is anticipated during the course of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): INH 300mg/RIF 600mg/PZA 20mg/kg/MOX 400mg/EMB placebo once daily for 8 weeks
- 2 (Type: PLACEBO_COMPARATOR): INH 300mg/RIF 600mg/PZA 20mg/kg/MOX placebo/EMB 15-20mg/kg once daily for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: New Approach for Treatment of Behavioral Disorders in Alzheimer's Disease (Alzheimer's Behavioral and Cognitive Disorders)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Person with Alzheimer's disease.~Exclusion Criteria:~* Bedridden patients.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental group (TR) (Type: EXPERIMENTAL): A group of 80 patients with AD will perform a program of EET for 2 hours a day, 5 days a week for a total of 6 months.
- Control group (CTRL) (Type: NO_INTERVENTION): A group of 80 patients with AD will be treated with the standard therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Diclofenac Sodium Gel in Hand Osteoarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Key Inclusion criteria:~• Osteoarthritis of the hand~Key Exclusion Criteria:~* Other rheumatic disease, such as rheumatoid arthritis~* Active gastrointestinal ulcer during the last year~* Known allergy to analgesic drugs

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Clinical Efficacy and Safety of Tobradex® ST Compared to Azasite® in the Treatment of Subjects With Moderate to Severe Chronic Blepharitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have diagnosis of moderate to severe chronic blepharitis defined by a minimum score of at least 1 for one of the lid signs, one of the conjunctival signs, and one of the symptoms in at least one eye~* Have a minimum global score (the total signs and symptoms score) of 5 in the same eye qualifying.~Exclusion Criteria:~* Have known sensitivity or poor tolerance to the test article (tobramycin, dexamethasone, azithromycin) or its components or any therapy associated with the trial~* Have a history of ocular surgical intervention within six (6) weeks prior to Visit 1 or during the study~* Have any ocular infections (bacterial, viral or fungal) - active ocular inflammation (i.e. follicular conjunctivitis, iritis) or preauricular lymphadenopathy, other than blepharitis~* Have worn contact lenses in the 72 hours prior to visit 1 and for the duration of the study~* Are currently taking any medication known to cause ocular drying that has not been on a stable dose for at least 30 days~* Have used any topical ocular or systemic antibiotics within 7 days of enrollment. Stable (greater than 1 month prior to enrollment) use of topical antibiotics on the face (except around the eyes) for dermatologic conditions is allowed. Dose must continue unchanged for duration of study~* Have used any topical ocular - aerosolized/nebulized - or systemic corticosteroid agents within 14 days of enrollment. Stable (greater than 1 month prior to enrollment) use of inhaled (using mouthpiece) and nasal corticosteroids and topical dermal steroids (except around the eyelids) are allowed. Dose must continue unchanged for the duration of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tobradex ST (Type: EXPERIMENTAL): tobramycin 0.3%, dexamethasone 0.05%
- Azasite (Type: ACTIVE_COMPARATOR): azithromycin 1%

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Gaucher Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has a documented diagnosis of type 1 Gaucher disease, as determined by deficient glucocerebrosidase (GCB) activity relative to normal as measured in leukocytes or by genotype analysis and is willing and able to provide written informed consent prior to initiating any study-related procedures~* Patient is at least 2 years of age~* Patient has Gaucher disease-related anemia and~* Patient has at least moderate splenomegaly or~* Patient has Gaucher disease-related thrombocytopenia or~* Patient has a readily palpable enlarged liver~* Patient has not received treatment for Gaucher disease within 30 months prior to study entry~* Female patients of child-bearing potential agree to use a medically acceptable method of contraception. Male patients must agree to use a medically acceptable method of birth control.~* Patient must be sufficiently cooperative to participate in the study as judged by the Investigator.~Exclusion Criteria:~Includes:~* Patient has type 2 or 3 Gaucher disease or is suspected of having type 3 Gaucher disease~* Patient is antibody-positive to imiglucerase during screening or has experienced an anaphylactic reaction to imiglucerase~* Patient has received treatment with any investigational drug or device within the 30 days prior to study entry~* Patient is Human immunodeficiency virus (HIV) positive~* Patient is hepatitis positive~* Patient presents with iron, folic acid and/or vitamin B12 deficiency sustained anemia during screening~* Patient, patient's parent(s), or patient's legal guardian(s) is/are unable to understand the nature, scope, and possible consequences of the study~* Patient has a significant comorbidity(ies)that might affect study data or confound the study results~* Patient is a pregnant and/or lactating female~* Patient is unable to comply with the protocol or is unlikely to complete the study, as determined by the Investigator

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VPRIV®-45 U/kg, IV, every other week (Type: EXPERIMENTAL): VPRIV® (velaglucerase alfa, Gene Activated® human glucocerebrosidase, GA-GCB)
- VPRIV®-60 U/kg, IV, every other week (Type: EXPERIMENTAL): VPRIV® (velaglucerase alfa, Gene Activated® human glucocerebrosidase,GA-GCB)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PNU-100480 In Newly Diagnosed, Drug Sensitive Patients With Pulmonary TB; Early Bactericidal Activity; Whole Blood Assay

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult males or females between 18 and 65 years; women of childbearing potential must be willing to adhere to lifestyle requirements regarding contraception/pregnancy prevention.~* Newly diagnosed sputum smear-positive pulmonary TB confirmed with acid-fast bacillus (AFB) smear and chest x-ray. Patients with TB more than 5 years ago who completed treatment, are healthy, and meet other inclusion criteria may be included.~* Body weight between 40 and 90 kg, inclusive (in light clothing, no shoes).~* Reasonably normal hemoglobin (\>=8 gm/dL), renal function (serum creatinine \<2 mg/dL), hepatic function (serum AST \<3xULN and total bilirubin \<1.3 mg/dL), and random glucose \<150 mg/dL.~Exclusion Criteria:~* HIV infection with helper/inducer T-lymphocytes (CD4 cell) count of \<=350x10-6/L.~* Presence of significant hemoptysis. Subjects who cough up frank blood (more than blood streaked sputum) will not be eligible.~* Pregnant or nursing females; females of childbearing potential unwilling or unable to adhere to contraception guidelines.~* Significant respiratory impairment (respiratory rate \>35/minute).~* Clinical suspicion of disseminated TB or tuberculosis meningitis.~* Subjects with diabetes mellitus on insulin and/or who have poorly controlled disease.~* Subjects with confirmed or suspected multi-drug resistant TB.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- PNU-100480 600 mg BID (Type: EXPERIMENTAL): None
- PNU-100480 1200 mg QD (Type: EXPERIMENTAL): None
- RHZE (Type: ACTIVE_COMPARATOR): conjugated tablet with 4 drug combination of RHZE, Rifafour® e275 will be used in countries where can be sourced locally

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intravenous Infusions of Ferumoxytol Compared to Oral Ferrous Sulfate for the Treatment of Anemia in Pregnancy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Maternal age \>/= 18~* Singleton gestation~* \>/=20 weeks gestation, \<37 weeks gestation~* Hemoglobin \<11g/dL and/or hematocrit \<33%~* Able to read/speak English or Spanish~Exclusion Criteria:~* Maternal age \<18~* Multiple gestation~* \<20 weeks gestation, \</= 37 weeks gestation~* Hemoglobin \>/=11g/dL and/or hematocrit \>/=33%~* Unable to read or speak English or Spanish~* Incarcerated patients

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Ferumoxyltol (Type: EXPERIMENTAL): Patients will receive two infusions of Ferumoxyltol, 510mg, intravenously, one week apart.~Iron studies will be completed at study inclusion and again at presentation for delivery. Cord blood will also be assessed for iron studies.
- Ferrous Sulfate (Type: ACTIVE_COMPARATOR): Patients will be provided with oral ferrous sulphate, 325mg, to take 2x daily at home.~Iron studies will be completed at study inclusion and again at presentation for delivery. Cord blood will also be assessed for iron studies.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study of KW-0761 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Positive for serum anti-HTLV-I antibody~2. Acute-, lymphoma-, or chronic-type with poor prognostic factors specified in the past~3. Positive for CCR4~4. Relapsed subject after the response (CR, CRu or PR) in the last previous chemotherapy~5. Received at least one prior chemotherapy~6. Subjects with an interval of four weeks or more between the last day of the previous treatment and the scheduled day of the first KW-0761 treatment~7. PS of 0 to 2~8. Negative for HBs antigen and for HBV-DNA by a real-time PCR~Exclusion Criteria:~1. A history of transplantation such as hematopoietic stem cells~2. Positive for HCV antibody or HIV antibody~3. Active multiple cancers at the time of starting this clinical study~4. Previous history of allergic reactions after receiving antibody products~5. Requiring continuous systemic treatment with a steroid~6. Requiring such radiotherapy after starting this clinical study~7. Treated with any investigational drug other than KW-0761 within three months

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- KW-0761 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Intravenous Aflibercept With Docetaxel in Chinese Patients With Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria :~* Histologically or cytologically confirmed solid malignancy that metastatic or unresectable for which standard curative measures do not exist, but for which docetaxel treatment is appropriate.~Exclusion criteria :~* Squamous histology/cytology lung cancer~* Need for a major surgical procedure or radiation therapy during the study~* Treatment with chemotherapy, hormonal therapy, radiotherapy, surgery, or an investigational agent within 28 days~* Cumulative radiation therapy to \>25% of the total bone marrow~* History of brain metastases~* Eastern Cooperative Oncology Group(ECOG)\>1~* Prior docetaxel treatment but have not been appropriate for safety reasons~* Inadequate organ and bone marrow function~* Uncontrolled hypertension~* Evidence of clinically significant bleeding diathesis or underlying coagulopathy~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aflibercept/ docetaxel (Type: EXPERIMENTAL): Patients with advanced cancer will receive different doses of aflibercept in combination with approved dose of docetaxel.~Aflibercept 4 or 6mg/kg over 1 hour IV immediately followed by Docetaxel 75mg/m2 IV over 1 hour on Day 1, every 3 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete